Market news
BeyondSpring received FDA Fast Track designation for Plinabulin plus docetaxel in post-ICI non-squamous NSCLC and announced a strategic transaction designed to reduce the cash required to advance its global Phase 3 DUBLIN-4 trial toward a prespecified interim analysis. Key Investor TakeawaysBeyondSpring (NASDAQ:BYSI) received FDA Fast Track designation for Plinabulin plus docetaxel in advanced or metastatic non-squamous NSCLC following prior anti-PD-(L)1 therapy and platinum chemotherapy.
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of
This is the newest page. Registered accounts read further back.